Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Lumos Pharma Inc | LUMO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.62 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 2.41 - 4.55 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 2.62 | USD |
Lumos Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
7.22M | 8.11M | - | 2.05M | -34.03M | -4.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Lumos Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LUMO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.73 | 2.76 | 2.41 | 2.53 | 17,757 | -0.11 | -4.03% |
1 Month | 2.84 | 2.95 | 2.41 | 2.67 | 10,962 | -0.22 | -7.75% |
3 Months | 2.78 | 3.303 | 2.41 | 2.92 | 20,194 | -0.16 | -5.76% |
6 Months | 4.11 | 4.55 | 2.41 | 3.61 | 76,927 | -1.49 | -36.25% |
1 Year | 3.34 | 4.55 | 2.41 | 3.58 | 48,949 | -0.72 | -21.56% |
3 Years | 11.97 | 13.59 | 2.41 | 5.80 | 33,630 | -9.35 | -78.11% |
5 Years | 8.59 | 36.72 | 2.41 | 8.49 | 34,184 | -5.97 | -69.50% |
Lumos Pharma Description
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States. |